J Biotechnol Biomater 2019, Volume 9
DOI: 10.4172/2155-952X-C2-116

Human papillomavirus (HPV): Systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus

Hanan Polansky, Edan Itzkovitz and **Adrian Javaherian**
The Center for the Biology of Chronic Disease, USA

This paper reports the results of a clinical study that tested the effect of systemic treatment with the botanical product Gene-Eden-VIR/Novirin on the clearance rate (also called time to clearance) of the human papillomavirus (HPV). The study compared the clearance rate in treated and untreated individuals suffering from a symptomatic HPV infection. The mean time to clearance in Gene-Eden-VIR/Novirin treated individuals was 5.1 months or 151.5 days (95% CI: 4.2-5.9 months or 95% CI: 125.7-177.3 days respectively). The median time to clearance was 3.5 months. The mean time to clearance in the five untreated groups ranged from 6.9 to 20.0 months ($P<0.0001$ for the difference between treatment group and each untreated group). Also, 100% of the participants in the treatment group were HPV free at the end of 12 months vs., 53%, 52%, 65%, 20%, and 77% in the untreated control groups. The treated participants reported no adverse experiences. This clinical study has two major contributions. First, it showed that systemic treatment with the natural Gene-Eden-VIR/Novirin decreased the time of HPV clearance, increased the percentage of HPV free individuals and caused no adverse experiences in individuals suffering from a symptomatic HPV infection. Since, there are no other systemic treatments for symptomatic HPV infections, this study presents highly valuable information on the clinical effects of the first treatment in this category. Secondly, the study presents a new method for conducting clinical studies that addresses one of the major deficiencies associated with the practice of the randomized controlled trial method.

hpolansky@cbcd.net